Table 2.

Demographic and breast cancer clinical characteristics.

Characteristic	HIV-negative (N = 159)		HIV-positive (N = 166)		P-value1
	n	%	n	%
Age (years)					<.0001
<40	23	14.5	36	21.7
40-50	43	27.0	89	53.6
50-60	45	28.3	31	18.7
60-70	30	18.9	9	5.4
≥70	18	11.3	1	0.6
Marital status					.02
Married	58	36.5	40	24.2
Unmarried	101	63.5	125	75.8
Education					.04
None/some primary	32	20.1	15	9.1
Primary	60	37.7	69	42.1
Secondary	51	32.1	65	39.6
Post-secondary	16	10.1	15	9.1
Wealth index (percentile)					.11
<20th	49	30.8	49	29.5
20-40th	26	16.4	46	27.7
40-60th	29	18.2	21	12.7
60-80th	26	16.4	20	12.0
≥80th	29	18.2	30	18.1
Treating hospital					.75
CMJAH	94	59.1	101	60.8
GH	65	40.9	65	39.2
Year of diagnosis					.02
2015	22	13.8	19	11.4
2016	34	21.4	59	35.5
2017	33	20.8	41	24.7
2018	50	31.4	32	19.3
2019	20	12.6	15	9.0
Stage					.24
I	4	2.5	10	6.1
II	54	34.0	49	29.7
III	101	63.5	106	64.2
Grade					.53
1	12	7.7	14	8.6
2	74	47.7	86	53.1
3	69	44.5	62	38.3
ER/PR status					.46
Positive	126	79.7	126	76.4
Negative	32	20.3	39	23.6
HER2 status					.20
Positive	35	22.2	41	24.8
Negative	108	68.4	99	60.0
Equivocal	15	9.5	25	15.2
Pre-chemotherapy ECOG performance status					.92
0	118	74.2	121	72.9
1	39	24.5	43	25.9
2	2	1.3	2	1.2
Post-chemotherapy ECOG performance status					.74
0	119	75.3	121	75.2
1	35	22.2	38	23.6
2	4	2.5	2	1.2
Missing	1		5
Antiretroviral medication use at enrollment					—
Yes	—	—	139	83.7
No	—	—	27	16.3
CD4 cell count at enrollment (cells/mL)					—
<500	—	—	75	46.3
≥500	—	—	87	53.7
HIV viral load (viral copies/mL)					—
≤50	—	—	61	53.0
>50	—	—	54	46.0

¹ Chi-square testing.

Abbreviations: CMJAH, Charlotte Maxeke Johannesburg Academic Hospital; ER/PR Estrogen receptor/progesterone receptor; GH, Grey’s Hospital; HER2, human epidermal growth factor receptor 2.